Urokinase is a traditional thrombolytic drug which has been operated in
China for many years. It is widely used in a variety of vascular embolism
diseases such as acute myocardial infarction, cerebral thrombosis, pulmonary
vein thrombosis, and lower limb vein thrombosis. This project used molecular
design and gene site-directed mutation technology to obtain urokinase provariant
gene (patented), and to prepare urokinase variant (Super UK) through escherichia
coli genetic engineering. Urokinase was obtained by this method without
fibrinolytic enzyme activation, and directly changed into urokinase under the
action of its intrinsic enzyme activity, without any human raw materials, and
without any potential risk of virus contamination.
Urokinase is mainly used for thrombolytic treatment of thromboembolic
diseases. These included acute generalized pulmonary embolism, coronary artery
embolization and myocardial infarction within 6-12 hours of chest pain, acute
stage cerebral embolization with symptoms shorter than 3-6 hours, retinal artery
embolization, and other severe peripheral arterial embolization of ilio-femoral
vein thrombosis. It is also used to prevent thrombus formation after artificial
heart flap operation, and to keep the vascular intubation and the thoracic
cavity and pericardial cavity drainage tube unobtrusive.